The Djavad Mowafaghian Centre for Brain Health has topped 193 research sites around the world having recruited the most participants for an international clinical trial investigating the efficacy of a new multiple sclerosis (MS) drug called ocrelizumab.
“A good centre could maybe get as many as 10 recruits for a study – we had 59,” says Dr. Anthony Traboulsee, associate professor in the University of British Columbia Department of Medicine (Neurology) and director of the UBC Hospital MS and NMO Clinic.
